Marfan Syndrome
Conditions
Keywords
Marfan Syndrome, Large arterial function, LV function, atenolol, perindopril, verapamil, central arterial pressure
Brief summary
The investigators are looking at the different impacts of atenolol, verapamil and perindopril on large artery and lv function in marfan syndrome. It is a double-blind, randomised cross-over trial.
Detailed description
The investigators recruited 21 patients with confirmed diagnosis of Marfan syndrome from two centres. The investigators performed radial artery applanation tonometry and pulse wave analysis to derive central aortic pressure and haemodynamic indexes pre-and post administering Atenolol 75mg, Perindopril 4mg and Verapamil 240mgs each for four weeks with a two week wash-out between medications. All patients underwent detailed functional and anatomical echocardiographic assessments at each visit. Inclusion criteria were ages 16-60 years with no treatment or β-blocker or other monotherapy only for Marfan syndrome. Patients with previous aortic dissection or aortic surgery, severe valvular regurgitation, aortic diameter at the sinotubular junction ≥ 5.0cm, contraindications to specific drug treatment, e.g. asthma and β-blocker, or those who were pregnant or at risk of pregnancy were excluded.
Interventions
240 MG SR
4 MG
Sponsors
Study design
Eligibility
Inclusion criteria
* Ages 16-60 years old with no treatment or β-blocker or other monotherapy only for Marfan syndrome
Exclusion criteria
* Previous aortic dissection or aortic surgery * Severe valvular regurgitation * Aortic diameter at the sinotubular junction ≥ 5.0cm * Contraindications to specific drug treatment, e.g. asthma and β-blocker * Those who were pregnant or at risk of pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CENTRAL ARTERIAL PRESSURE | 18 weeks | CENTRAL ARTERIAL PRESSURE MEASURED BY APPLANATION TONOMETRY |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| LARGE ARTERIAL STIFFNESS INDICES | 18 WEEKS | MEASURED BY ECHO AND BY PULSE WAVE VELOCITY/ANALYSIS BY APPLANATION TONOMETRY |
| LV Function | 18 WEEKS | GLOBAL AND REGIONAL MARKERS BY ECHO |
Countries
United Kingdom